Katherine Fuh, MD, PhD

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms.

Rethinking ovarian cancer III: the past decade and future directions.

Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery?